BACKGROUND: Chemotherapy-induced @entity1209 (CINV) can lead to increased emergency department visits and hospitalizations, which may contribute to increased cost of care. Antiemetic agents, such as neurokinin-1 (NK1) receptor antagonists and @entity750 (5-HT3) receptor antagonists, are prescribed for @entity1 receiving highly emetogenic chemotherapy (HEC) and @entity7730 ( @entity7730 ). The current guidelines recommend a 3-drug combination of an @entity9766 antagonist, a 5-HT3 receptor antagonist, and @entity619 with HEC regimens and certain @entity7730 regimens. OBJECTIVE: To compare the incidence of CINV and CINV-related resource utilization among @entity1 who receive guideline-adherent HEC and @entity7730 regimens and @entity1 who receive non-guideline-adherent regimens. METHODS: In this retrospective, claims-based study, Inovalon's Medical Outcomes Research for Effectiveness and Economics Registry (MORE2 Registry) Research Edition database was used to identify 8089 @entity1 with solid @entity5 receiving therapy with @entity5948 plus @entity786 (AC), @entity900 , or @entity3003 from June 2013 to December 2013. The @entity1 were stratified according to the use of an @entity9766 antagonist regimen. International Classification of Diseases, Ninth Revision, Clinical Modification codes were used to identify CINV events associated with hospital, emergency department, and outpatient office visits among @entity1 in the @entity9766 antagonist group and the non- @entity9766 antagonist group. RESULTS: A total of 1059 @entity1 were included in the analysis, of whom 51% (N = 536) used an @entity9766 antagonist-based regimen and 49% (N = 523) used non- @entity9766 antagonist therapy. A higher percentage of @entity1 receiving AC (73%) than @entity900 (56%) or @entity3003 (23%) received an @entity9766 antagonist. The incidence rates of total CINV events and CINV-related emergency department visits were lower in the group receiving an @entity9766 antagonist (44% and 9%, respectively) than in the group receiving a non- @entity9766 antagonist (50% and 15%, respectively). CONCLUSION: The @entity1 receiving an @entity9766 antagonists had a lower rate of resource utilization, suggesting that the use of @entity9766 antagonist-containing regimens according to current national guidelines may reduce healthcare resource utilization, such as CINV-related office, hospital, and emergency department visits for @entity1 receiving highly and @entity7730 .

Resource Utilization for Chemotherapy-Induced XXXX Events in @entity1 with @entity5 Treated with Antiemetic Regimens.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity9766 :: ('6869', 'Gene') :: ['NK1 receptor'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors'] @entity5948 :: ('D018943', 'Chemical') :: ['anthracycline'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone'] @entity750 :: ('MESH:D012701', 'Chemical') :: ['5-hydroxytryptamine'] @entity7730 :: ('MESH:D064146', 'Disease') :: ['MEC', 'moderately emetogenic chemotherapy'] @entity1209 :: ('MESH:D020250', 'Disease') :: ['nausea and vomiting']
@entity1209 :: (MESH:D020250,Disease) :: ['Nausea and Vomiting']
